Judah Frommer
Stock Analyst at Morgan Stanley
(4.04)
# 545
Out of 5,138 analysts
187
Total ratings
59.85%
Success rate
8.94%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $118.84 | +22.01% | 4 | Jan 9, 2026 | |
| BLTE Belite Bio | Initiates: Overweight | $191 | $160.01 | +19.37% | 1 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Downgrades: Equal-Weight | $37 → $19 | $20.88 | -9.00% | 2 | Jan 6, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $18.40 | +95.65% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $10.42 | +82.34% | 2 | Nov 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $20.47 | +27.02% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $25.14 | +71.04% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $14.10 | +70.21% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $33.50 | -34.33% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $7.62 | -21.26% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $72.17 | +46.88% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $16.72 | +109.33% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.14 | +40.19% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.54 | +2,497.40% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.86 | +598.92% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $72.46 | -58.60% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $28.72 | -19.92% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $73.07 | -31.57% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $21.04 | +570.15% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.85 | +133.77% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $32.41 | -32.12% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.92 | +18.24% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $10.60 | -24.53% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $72.90 | -36.90% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.89 | +142.21% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $22.40 | +145.54% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $163.51 | -71.87% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $95.35 | -48.61% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $964.26 | -61.63% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $83.44 | -62.85% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $76.52 | -0.68% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $146.63 | +24.12% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $134.06 | -20.18% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $114.21 | -16.82% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.14 | +5.02% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $191.22 | -39.34% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $92.17 | -58.77% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $72.55 | -69.68% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $63.15 | -44.58% | 9 | Apr 29, 2020 |
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $118.84
Upside: +22.01%
Belite Bio
Jan 6, 2026
Initiates: Overweight
Price Target: $191
Current: $160.01
Upside: +19.37%
Zenas BioPharma
Jan 6, 2026
Downgrades: Equal-Weight
Price Target: $37 → $19
Current: $20.88
Upside: -9.00%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $18.40
Upside: +95.65%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $10.42
Upside: +82.34%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $20.47
Upside: +27.02%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $25.14
Upside: +71.04%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $14.10
Upside: +70.21%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $33.50
Upside: -34.33%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $7.62
Upside: -21.26%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $72.17
Upside: +46.88%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $16.72
Upside: +109.33%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.14
Upside: +40.19%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.54
Upside: +2,497.40%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.86
Upside: +598.92%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $72.46
Upside: -58.60%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $28.72
Upside: -19.92%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $73.07
Upside: -31.57%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $21.04
Upside: +570.15%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.85
Upside: +133.77%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $32.41
Upside: -32.12%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.92
Upside: +18.24%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $10.60
Upside: -24.53%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $72.90
Upside: -36.90%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.89
Upside: +142.21%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $22.40
Upside: +145.54%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $163.51
Upside: -71.87%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $95.35
Upside: -48.61%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $964.26
Upside: -61.63%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $83.44
Upside: -62.85%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $76.52
Upside: -0.68%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $146.63
Upside: +24.12%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $134.06
Upside: -20.18%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $114.21
Upside: -16.82%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.14
Upside: +5.02%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $191.22
Upside: -39.34%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $92.17
Upside: -58.77%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $72.55
Upside: -69.68%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $63.15
Upside: -44.58%